Tempo Therapeutics develops materials that are immune stealth, minimally invasive, and precision-engineered for regenerative medicine.
Tempo Therapeutics has raised $2.3M in total funding. The most recent round was Grant. The last funding was announced in September 2026.
Tempo Therapeutics's investors include National Science Foundation, Gideon Strategic Partners, Mesa Verde Venture Partners, Johnson & Johnson, YK Bioventures.
Tempo Therapeutics is headquartered in San Diego, United States.
Tempo Therapeutics develops materials that are immune stealth, minimally invasive, and precision-engineered for regenerative medicine.
Tempo Therapeutics is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Tempo Therapeutics — Funding & Investors." VCBacked, September 23, 2026, https://www.vcbacked.co/company/tempo-therapeutics. Accessed November 12, 2026.
VCBacked. (2026). Tempo Therapeutics — Funding & Investors. Retrieved November 12, 2026, from https://www.vcbacked.co/company/tempo-therapeutics
{{cite web |title=Tempo Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/tempo-therapeutics |website=VCBacked |access-date=November 12, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Tempo Therapeutics? Request a listing update